Goldman Sachs’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $410M | Buy |
4,435,839
+1,808,130
| +69% | +$182M | 0.05% | 402 |
|
|
2025
Q4 | $268M | Buy |
2,627,709
+1,121,499
| +74% | +$100M | 0.03% | 517 |
|
|
2025
Q3 | $94.1M | Buy |
1,506,210
+359,505
| +31% | +$19.6M | 0.01% | 985 |
|
|
2025
Q2 | $59.7M | Sell |
1,146,705
-20,577
| -2% | -$919K | 0.01% | 1209 |
|
|
2025
Q1 | $49.7M | Sell |
1,167,282
-323,443
| -22% | -$14M | 0.01% | 1231 |
|
|
2024
Q4 | $45.5M | Buy |
1,490,725
+263,833
| +22% | +$7.42M | 0.01% | 1374 |
|
|
2024
Q3 | $28.1M | Sell |
1,226,892
-21,158
| -2% | -$599K | ﹤0.01% | 1749 |
|
|
2024
Q2 | $36M | Buy |
1,248,050
+47,250
| +4% | +$1.1M | 0.01% | 1403 |
|
|
2024
Q1 | $24.8M | Buy |
1,200,800
+291,030
| +32% | +$6.24M | ﹤0.01% | 1656 |
|
|
2023
Q4 | $24.6M | Sell |
909,770
-44,165
| -5% | -$1.16M | ﹤0.01% | 1722 |
|
|
2023
Q3 | $28.3M | Buy |
953,935
+322,171
| +51% | +$11.3M | 0.01% | 1502 |
|
|
2023
Q2 | $22.6M | Sell |
631,764
-301,066
| -32% | -$8.65M | ﹤0.01% | 1741 |
|
|
2023
Q1 | $21.9M | Buy |
932,830
+55,801
| +6% | +$1.59M | 0.01% | 1747 |
|
|
2022
Q4 | $23.9M | Sell |
877,029
-268,690
| -23% | -$12.3M | 0.01% | 1784 |
|
|
2022
Q3 | $61.7M | Sell |
1,145,719
-46,974
| -4% | -$2.41M | 0.02% | 974 |
|
|
2022
Q2 | $48.1M | Sell |
1,192,693
-504,253
| -30% | -$25M | 0.01% | 1149 |
|
|
2022
Q1 | $112M | Sell |
1,696,946
-55,877
| -3% | -$3.82M | 0.02% | 699 |
|
|
2021
Q4 | $175M | Buy |
1,752,823
+145,296
| +9% | +$15M | 0.03% | 510 |
|
|
2021
Q3 | $201M | Buy |
1,607,527
+9,783
| +0.6% | +$1.16M | 0.04% | 418 |
|
|
2021
Q2 | $198M | Buy |
1,597,744
+210,594
| +15% | +$28.3M | 0.04% | 413 |
|
|
2021
Q1 | $212M | Buy |
1,387,150
+84,285
| +6% | +$12.7M | 0.05% | 350 |
|
|
2020
Q4 | $168M | Buy |
1,302,865
+131,709
| +11% | +$15.2M | 0.04% | 395 |
|
|
2020
Q3 | $131M | Buy |
1,171,156
+495,996
| +73% | +$45.4M | 0.04% | 466 |
|
|
2020
Q2 | $54.8M | Buy |
675,160
+62,414
| +10% | +$5.03M | 0.02% | 886 |
|
|
2020
Q1 | $42.6M | Buy |
612,746
+59,321
| +11% | +$4.55M | 0.02% | 977 |
|
|
2019
Q4 | $43.2M | Buy |
553,425
+85,591
| +18% | +$6.17M | 0.01% | 1261 |
|
|
2019
Q3 | $29.9M | Buy |
467,834
+11,177
| +2% | +$985K | 0.01% | 1487 |
|
|
2019
Q2 | $39.4M | Buy |
456,657
+232,397
| +104% | +$17.7M | 0.01% | 1319 |
|
|
2019
Q1 | $17.2M | Sell |
224,260
-77,488
| -26% | -$4.3M | 0.01% | 2002 |
|
|
2018
Q4 | $11.3M | Buy |
+301,748
| New | +$11.1M | ﹤0.01% | 2256 |
|
Other funds holding GH
VPM
VCM
Goldman Sachs's GH Position: Q1 2026 in Review
Goldman Sachs increased its Guardant Health (GH) stake by 69% in Q1 2026, buying an estimated $182M and bringing the position to 4,435,839 shares worth $410M. The position accounts for 0.05% of the portfolio, ranked #402.
Goldman Sachs first reported a position in GH in Q4 2018 and has held it in 30 quarters since. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.
- Goldman Sachs held 4,435,839 shares of Guardant Health worth $410M as of Q1 2026.
- Goldman Sachs bought 1,808,130 Guardant Health shares in Q1 2026, an estimated $182M.
- Guardant Health made up 0.05% of Goldman Sachs's portfolio in Q1 2026, its #402 holding.
- Goldman Sachs first reported a position in Guardant Health in Q4 2018 and has held it in 30 quarters since.
- 481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.